Polymorphism in the pharmaceutical industry by Rolf Hilfiker
Download eBook
Polymorphism in the pharmaceutical industry Rolf Hilfiker ebook
Publisher: Wiley-VCH
Format: pdf
ISBN: 3527311467, 9783527311460
Page: 433
Download Polymorphism in the pharmaceutical industry. Lack of control could be due to variation in particle sizes or to changes in crystallinity (i.e. 8 years experience from pharmaceutical industry within the area of physical characterisation. Then based on those findings, and on the In the meantime, these companies are selling their services to pharmaceutical companies for research into new drugs to fill this soon-to-be-discovered future need – gearing up to create a new pipeline for the drug trade. Polymorphism in the pharmaceutical industry. The isolation of human cytochrome P450s by the Guengerich group introduced a way for the pharmaceutical industry to test drugs for human toxicity before they are developed and released into the market. [0005] In the literature various polymorphic forms of sertraline hydrochloride have been described. Abstract: The polymorphic stability of a drug substance is a very important topic in the pharmaceutical industry. Integrated Process Research and Development by Solvias: Basis of an Efficient and Successful Drug Substance Development in the Pharma Industry. In light of current interest of pharmaceutical industry, the polymorphic Form V is of very much importance (WO 00/32551). Guengerich Human Liver Microsomal Cytochrome P-450 Mephenytoin 4-Hydroxylase, a Prototype of Genetic Polymorphism in Oxidative Drug Metabolism. Purification and Characterization of Allan Conney at Rutgers University. Category: Drug Solid state investigations including salt selection, polymorphism screening, and crystallization optimization programs enable customers to prepare the optimal solid form of a drug substance with well-defined properties for manufacture of the corresponding drug product. Polymorphism in the pharmaceutical industry by Rolf Hilfiker. Our development of a new synthesis By implementing our expertise in the areas of polymorphism and the synthesis of active ingredients, we delivered the desired results. Ten or 20 years from now, we will be sending our patients to the laboratory to characterize them in terms of genetic polymorphisms and/or to an imaging laboratory. As an independent firm with extensive experience in the pharmaceutical industry and wide-ranging technological expertise, Solvias is your preferred partner for challenging synthesis and crystallization projects.